Efficacy and safety of venetoclax-based regimens versus intensive chemotherapy in older adults with newly diagnosed acute myeloid leukemia: a single-center retrospective study.

Venetoclax (VEN) has emerged as a frontline therapy for older adults with acute myeloid leukemia (AML), yet its advantages over intensive chemotherapy (IC) remain uncertain. This single-center retrospective study compared the efficacy and safety of V…

Preview only. Read the full abstract at the source